TP53 and cholangiocarcinoma: Since heteronemin inhibited p53 expression in cholangiocarcinoma [2] and in both oral cancer cell lines (Figure 2), we examined if the combined treatment of 10−7 M tetrac with different concentrations of heteronemin would change p53 expression.